Literature DB >> 31332063

In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model.

Miao Zhao1,2, Alexander J Lepak1, Karen Marchillo2, David R Andes3,4,2.   

Abstract

Delafloxacin is a broad-spectrum anionic fluoroquinolone that has completed a phase 3 study for community-acquired bacterial pneumonia. We investigated the pharmacodynamic target for delafloxacin against 12 Klebsiella pneumoniae and 5 Pseudomonas aeruginosa strains in the neutropenic murine lung infection model. The median 24-h free-drug area under the curve (fAUC)/MIC values associated with net stasis and 1-log kill were 28.6 and 64.1 for K. pneumoniae, respectively. The 24-h fAUC/MIC values associated with net stasis and 1-log kill for P. aeruginosa were 5.66 and 14.3, respectively.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Klebsiellazzm321990; Pseudomonas aeruginosazzm321990; delafloxacin; pharmacodynamics

Year:  2019        PMID： 31332063      PMCID： PMC6761510          DOI： 10.1128/AAC.01131-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.

Authors:  Abrar K Thabit; Jared L Crandon; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2016-09-29       Impact factor: 5.283

2.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.

Authors:  Randall Hoover; Thomas Hunt; Michael Benedict; Susan K Paulson; Laura Lawrence; Sue Cammarata; Eugene Sun
Journal:  Clin Ther       Date:  2015-12-21       Impact factor: 3.393

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Authors:  Jennifer Shiu; Grace Ting; Tony Kl Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

5.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance.

Authors:  Olusegun O Soge; Stephen J Salipante; David No; Erin Duffy; Marilyn C Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.

Authors:  Alexander J Lepak; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

9.  In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.

Authors:  M A Pfaller; H S Sader; P R Rhomberg; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 10.  Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.

Authors:  Paul M Tulkens; Françoise Van Bambeke; Stephen H Zinner
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079
View more
  3 in total

1.  In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone.

Authors:  Kenneth C Fan; James Lin; Nicolas A Yannuzzi; Hasenin Al-Khersan; Nimesh A Patel; Jorge Maestre-Mesa; Mustafa Zaidi; Darlene Miller; Harry W Flynn
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-02-27

Review 2.  Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  L J Scott
Journal:  Drugs       Date:  2020-08       Impact factor: 9.546

Review 3.  Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.

Authors:  Rakel Arrazuria; Bernhard Kerscher; Karen E Huber; Jennifer L Hoover; Carina Vingsbo Lundberg; Jon Ulf Hansen; Sylvie Sordello; Stephane Renard; Vincent Aranzana-Climent; Diarmaid Hughes; Philip Gribbon; Lena E Friberg; Isabelle Bekeredjian-Ding
Journal:  Front Microbiol       Date:  2022-09-08       Impact factor: 6.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.